JPMorgan Chase & Co. started coverage on shares of GALAPAGOS NV/S (NASDAQ:GLPG) in a report released on Wednesday, The Fly reports. The brokerage set an “overweight” rating on the biotechnology company’s stock.

A number of other equities research analysts also recently issued reports on the company. Stifel Nicolaus increased their price objective on GALAPAGOS NV/S from $109.00 to $111.00 and gave the stock a “buy” rating in a research report on Wednesday. BidaskClub downgraded GALAPAGOS NV/S from a “hold” rating to a “sell” rating in a research report on Saturday. Goldman Sachs Group reiterated a “neutral” rating on shares of GALAPAGOS NV/S in a research report on Friday, August 17th. ValuEngine downgraded GALAPAGOS NV/S from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 17th. Finally, Zacks Investment Research downgraded GALAPAGOS NV/S from a “buy” rating to a “hold” rating in a research report on Wednesday, August 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $109.33.

Shares of GALAPAGOS NV/S stock traded up $16.97 during trading hours on Wednesday, reaching $119.71. The company had a trading volume of 985,600 shares, compared to its average volume of 104,914. GALAPAGOS NV/S has a one year low of $84.13 and a one year high of $122.28. The firm has a market capitalization of $4.89 billion, a P/E ratio of -45.34 and a beta of 2.03.

GALAPAGOS NV/S (NASDAQ:GLPG) last issued its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.91) by $0.41. GALAPAGOS NV/S had a negative return on equity of 13.26% and a negative net margin of 70.80%. The company had revenue of $59.27 million for the quarter, compared to the consensus estimate of $50.58 million. research analysts forecast that GALAPAGOS NV/S will post -3.12 earnings per share for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. DekaBank Deutsche Girozentrale bought a new position in GALAPAGOS NV/S in the first quarter valued at about $636,000. Victory Capital Management Inc. boosted its holdings in GALAPAGOS NV/S by 11.3% in the first quarter. Victory Capital Management Inc. now owns 20,356 shares of the biotechnology company’s stock valued at $2,031,000 after acquiring an additional 2,060 shares during the last quarter. Aperio Group LLC boosted its holdings in GALAPAGOS NV/S by 22.3% in the first quarter. Aperio Group LLC now owns 9,300 shares of the biotechnology company’s stock valued at $928,000 after acquiring an additional 1,697 shares during the last quarter. Employees Retirement System of Texas boosted its holdings in GALAPAGOS NV/S by 3.7% in the first quarter. Employees Retirement System of Texas now owns 56,000 shares of the biotechnology company’s stock valued at $5,587,000 after acquiring an additional 2,000 shares during the last quarter. Finally, Landscape Capital Management L.L.C. boosted its holdings in GALAPAGOS NV/S by 235.5% in the first quarter. Landscape Capital Management L.L.C. now owns 13,895 shares of the biotechnology company’s stock valued at $1,386,000 after acquiring an additional 9,754 shares during the last quarter. Institutional investors and hedge funds own 14.64% of the company’s stock.

About GALAPAGOS NV/S

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Read More: Average Daily Trade Volume Explained

The Fly

Analyst Recommendations for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.